Trial Profile
A Phase III, Open-label, 52week Study Evaluating the Safety and Efficacy of KRP-AB1102F DPI in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2016
Price :
$35
*
At a glance
- Drugs Aclidinium bromide/formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Kyorin Pharmaceutical
- 07 Jun 2016 New trial record